Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE CITRATE versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE CITRATE versus TOLECTIN 600.
IBUPROFEN AND DIPHENHYDRAMINE CITRATE vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing pain, fever, and inflammation. Diphenhydramine citrate is an antihistamine that antagonizes histamine H1 receptors, producing sedative and anticholinergic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Ibuprofen 200 mg + Diphenhydramine citrate 38 mg (equivalent to diphenhydramine HCl 25 mg) orally every 4-6 hours as needed, not to exceed Ibuprofen 1200 mg/day or Diphenhydramine citrate 152 mg/day.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Ibuprofen: terminal elimination half-life approximately 1.8-2.5 hours in adults; prolonged in elderly and patients with hepatic impairment. Diphenhydramine: terminal elimination half-life ranges from 4 to 10 hours (mean 7 hours); may be prolonged in elderly and hepatic impairment.
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Ibuprofen: renal elimination of metabolites (approximately 90%) and unchanged drug (approximately 10%); fecal elimination <5%. Diphenhydramine: primarily renal elimination (approximately 60-70% as metabolites, 1-2% unchanged); fecal elimination approximately 10-15%.
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category D/X
Category C
NSAID
NSAID